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Analysis of pupillometer results 
according to disease stage 
in patients with Parkinson’s disease
Sooyeoun You1, Jeong‑Ho Hong1 & Joonsang Yoo2*
We performed pupillometer testing on 132 patients with Parkinson’s disease, stratified into two 
groups according to the disease stage. Neurological examinations and pupillometry were performed 
in the ON state. Patients in the Hoehn and Yahr stages 1 and 2 comprised the early group, and patients 
in stages 3–5 formed the late group. We performed age‑ and sex‑matched (2:1) propensity score 
matching to compensate for the effect of age on pupil light reflex. Eight pupillometer parameters 
were measured and compared between the two groups. After the propensity score matching, the early 
group had 64 patients and the late group had 32 patients. The late group had a longer disease duration 
and took a higher levodopa equivalent dose than the early group. The constriction velocity (P = 0.006) 
and maximum constriction velocity (P = 0.005) were significantly faster in the early group than in 
the late group. Pupil size, minimum diameter, and dilation velocity were similar in both groups. The 
pupillary contraction velocity decreased with the disease progression, suggesting that the progression 
of Parkinson’s disease could be identified by the pupil constriction velocity.
The pupil light reflex (PLR) refers to the process of constriction and subsequent dilation of the pupil. It plays 
a major role in determining the retinal image quality and response to light. PLR is also an important measure 
of the autonomic nervous system function. Sphincter and dilators that are involved in modulating the PLR are 
innervated by parasympathetic and sympathetic nerves; therefore, several PLR parameters can be used as indica-
tors of either sympathetic or parasympathetic modulation. The measurement of PLR is a non-invasive method 
to determine the parasympathetic and sympathetic balance, and is a useful test for patients with neurological 
disorders. Factors affecting the average pupil diameter include age, sex, colors of the iris, optical media clarity, 
retinal and optic nerve health, and ambient light  level1.
Automated pupillometry is currently used to monitoring the nervous system functions of critically ill 
 patients2. In particular, the ability to measure pupillary function in a rapid, non-invasive, reliable, and quantifi-
able manner is of great help in the clinical diagnosis of critically ill patients in neuro-intensive care units. In 
addition, patients with neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease 
(PD), exhibit PLR abnormalities due to cholinergic  hypofunction3,4. In previous studies, compared with healthy 
age-matched subjects, patients with AD or PD, had significantly lowered maximum constriction velocity and 
maximum constriction amplitude, among the other components of  PLR5,6.
In previous studies on patients with PD, pupillometry results were helpful in detecting subclinical autonomic 
dysfunction; however they did not show a correlation with disease duration, the motor section of the Unified 
Parkinson’s disease rating scale (UPDRS), or with the presynaptic dopaminergic  dysfunction6,7. In this study, we 
investigated whether there is a relationship between the disease stage and pupillometry findings in PD patients.
Methods
This study was conducted by retrospectively reviewing the data of consecutive patients with PD who visited the 
outpatient department of neurology at Dongsan Medical Center between September 2019 and January 2020. This 
retrospective study was approved by the Institutional Review Board of Dongsan Hospital (IRB No. 2020-05-012) 
and requirement for informed consent was waived due to its retrospective nature. Our study was implemented 
in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.
Participants. PD was diagnosed according to the Movement Disorder Society (MDS) PD  Criteria8, and the 
examination was conducted by a movement specialist (S.Y.). We excluded patients with Parkinson-plus syn-
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dromes, such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration; patients 
diagnosed with vascular parkinsonism, drug-induced parkinsonism, AD, and other neurodegenerative diseases; 
patients with known ocular or systemic diseases, such as glaucoma, corneal damage, and uncontrolled diabetes 
mellitus, which could affect the PLR; and users of ocular topical agents with sympathomimetic or parasym-
pathomimetic effects. However, patients taking drugs with systemic anticholinergic effects (procyclidine and 
trihexyphenidyl) were not excluded.
Neurological examinations were performed in the ON state and de novo patients were excluded from this 
study. We also investigated the patients’ disease durations and levodopa equivalent daily doses (LEDD)9. The 
disease stage of the patients was measured using the Hoehn and Yahr (HY) rating scale. Patients belonging to 
HY stages 1 and 2 were classified as early stage, and those belonging to stages 3–5 were classified as late stage.
Pupillometry. The PLR was measured in both the eyes using a fully automated pupillometry system 
 (NPi®-200 Pupillometer, Neuroptics, CA), and eight parameters (neurological pupilar index [NPi], pupil size, 
maximum diameter, changing ratio of pupil size, constriction velocity, maximum constriction velocity, latency 
of constriction velocity, and dilation velocity) were obtained for each eye. For each variable, the mean value 
measured in both the eyes was used. PLR measurements were performed concurrently with the patients’ neu-
rological examinations, and tests were always performed at the same locations at a constant temperature and 
brightness.
Statistical analysis. Data are expressed as mean ± standard deviations, medians (interquartile range), or 
numbers (percentages), as statistically appropriate. We compared the pupillometric parameters between patients 
from early and late HY stages using Chi-square tests, Wilcoxon rank-sum tests, or Student’s t-test. To reduce the 
effects of aging on the pupillometric  parameters10,11, we performed propensity score matching. The propensity 
score was calculated using age and sex. After estimating the propensity score, the early and the late HY stage 
groups were matched at a ratio of 2:1. All P-values were two-tailed, and variables were considered significant at 
P < 0.05. All statistical analyses including the matching process were performed using R software version 4.0.3 (R 
Foundation for Statistical Computing, Vienna, Austria. http:// www.R- proje ct. org).
Results
Before propensity score matching. Among the 192 patients with Parkinsonism who visited the out-
patient clinic during the study period, data were reviewed for PD patients, while excluding 21 patients with 
Parkinson-plus syndrome (9 with progressive supranuclear palsy, 8 with multiple system atrophy, and 4 with 
corticobasal degeneration) and 4 with drug-induced parkinsonism (confirmed by dopamine transporter imag-
ing). Among the 167 remaining PD patients, 24 de novo patients and 11 with ocular or systemic diseases were 
excluded, and a total of 132 patients were finally analyzed (Fig. 1).
Among them, 100 patients (75.8%) were classified as early stage and 32 (24.2%) as late stage. Patients with 
late stage PD were older, had a longer duration of disease, and had a higher LEDD than those with early stage 
PD. There was no difference between the two groups in the proportion of patients using anticholinergics. In the 
pupillometry results, the late stage group had smaller pupil size and slower constriction velocity and maximum 
constriction velocity than the early stage group (Supplementary Table S1).
After propensity score matching. After 2:1 propensity score matching, there were 64 patients in the 
early stage and 32 patients in the late stage group. After matching, the age difference between the two groups 
decreased from 7 to 2 years, and the statistical differences in age between the two groups also disappeared. The 
late stage group had a longer disease duration (4 [2–7] years vs. 6 [4–9] years, P = 0.007) and a higher LEDD 
(387 ± 190 mg vs. 642 ± 296 mg, P < 0.001) than the early stage group. Constriction velocity (2.25 ± 0.64 mm/s 
vs. 1.89 ± 0.57  mm/s, P = 0.006) and maximum constriction velocity (3.31 ± 0.90  mm/s vs. 2.79 ± 0.80  mm/s, 
P = 0.005) were significantly lower in the late stage group than in the early stage group (Fig. 2).
However, baseline pupil size, minimum diameter, constriction latency, and dilation velocity were not signifi-
cantly different between the two groups (Table 1).
Discussion
In this study, we observed that PLR changes with the progression of disease stage in PD patients. Constriction 
velocity and maximum constriction velocity were significantly affected by the progression of PD, but there were 
no significant differences in variables such as minimum diameter and dilation velocities. The baseline pupil size 
was smaller in the late stage group, than in the early stage group, but after adjusting for age, the size difference 
disappeared, indicating that this difference may have been caused by age-related decrease in pupil  size11. Regard-
ing administration of systemic anticholinergic drugs, which is similar between two groups, and previous study 
also reported that the administration of these drugs did not affect the  PLR12.
It is well known that autonomic dysfunction occurs in  PD13. PLR is a phenomenon that is regulated by a typi-
cal automatic function involving both the sympathetic and parasympathetic pathways. Using the pupillometer, 
various parameters related to the PLR can be objectively measured. It is possible to determine autonomic dysfunc-
tion in an inexpensive, simple, and non-invasive way. Previous studies have reported that the constriction velocity 
in PD patients is lower than that in control groups, and there is a relationship between autonomic functions and 
PLR rate  changes6,14,15. However, little is known about whether the PLR is affected by disease progression in PD 
patients, and which parameters are affected.
Pupil constrictions are mainly related to the parasympathetic nervous system, wherein afferent light stimuli 
are transmitted to the pretectal neurons through retinal ganglia; these pretectal neurons are projected either 
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ipsilateral or contralateral, to the Edinger-Westphal nucleus (EWN). The preganglionic parasympathetic fiber 
from EWN forms a synapse in the ciliary ganglion through the oculomotor nerve, and postganglionic para-
sympathetic neurons secrete acetylcholine at the neuromuscular junction, resulting in pupil  constriction4. Pupil 
dilation occurs because of the following mechanisms: the sympathetic neuron from the reticular activation 
system located in the brainstem inhibits the preganglionic parasympathetic neuron in the EWN, and it synapses 
with the preganglionic neuron in the ciliospinal center of Budge at C8–T1. Finally, the contraction of the iris 
dilator muscle is caused by noradrenaline released from the postganglionic neuron, the long ciliary  nerve16. 
Pupillary abnormality with central parasympathetic involvement are well  known17, and pathologically, Lewy 
body accumulation and neuronal losses in the EWN are frequently  reported18. In addition, there are reports 
that the involvement of the striatal dopaminergic receptors is related to parasympathetic system  dysfunction19,20.
In our study, we observed a decrease in constriction velocity and maximum constriction velocity in a group 
with severe motor symptoms of PD. Constriction velocity and maximum constriction velocity are parameters 
involving the parasympathetic system, and changes in these parameters suggest that in patients with PD, the 
abnormalities of the PLR are mainly caused by parasympathetic autonomic dysfunctions. Among the pupil-
lometeric parameters, maximum constriction velocity is considered to be the most robust measure for detecting 
parasympathetic  dysfunction21.
In contrast, there was no significant difference in dilation velocity or minimum diameter between both the 
early stage and late stage PD patients. In previous studies, there was no difference in pupil diameter between PD 
and the control group after dark adaptation were  applied22–24. The PD group had longer latency and contraction 
times together with reduced contraction amplitudes, than the control  group22,25, and the peak constriction veloc-
ity of the PD group decreased than that of control  group26. Pupillometry studies conducted in AD patients have 
167 patients with Parkinson’s disease
24  De novo patients
132 patients enrolled the study
 8  Eye disease
 3  Systemic disease
156 patients
100 patients with early stage 32 patients with early stage
64 patients with early stage 32 patients with early stage
After Propensity score matching
192 patients with Parkinsonism
 21  Parkinson-plus syndrome
       9 Progressive supranuclear palsy
       8 Multiple system atrophy
       4 Corticobasal degeneration
  4  Drug induced parkinsonism
Figure 1.  Participants flow chart. The flowchart demonstrates the process of analyzing the pupillometry results 
of age- and sex-matched Parkinson’s disease patients.
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reported that their dilation and constriction velocities were significantly slower than healthy control group, and 
this finding is known to be associated with degenerative changes in the locus coeruleus (LC) in patients with 
 AD27. Since it is well known that neurodegenerative changes in LC appear in both AD and PD  patients28, further 
research is needed to discern why the sympathetic dysfunction measured by the PLR in advanced PD patients 
has not been identified. One explanation is that dilation velocity of all patients in our study was measured in the 
“ON” state, and taking dopaminergics may have an effect on the sympathetic nervous system, thereby offsetting 
the progression of PD on the dilation  velocity29,30.
This study had several limitations. First, it had a cross-sectional design and involved retrospective analyses. 
Although all patients who presented to our hospital during the study period were analyzed, there may have been 











Figure 2.  Comparison of constriction velocity, maximum constriction velocity, and dilation velocity between 
the early and the late stage groups. Constriction velocity and maximum constriction velocity decreased 
significantly in the late stage group. However, dilation velocity was similar between the two groups.
Table 1.  Characteristics of patients according to the HY stage. Values are presented as n (%), mean ± standard 
deviation or median [interquartile range]. HY Hoehn and Yahr, LEDD Levodopa equivalent daily dose, NPi 
Neurological pupil index.
Early stage (n = 64) Late stage (n = 32) P
Demographics
Age 71.8 ± 6.5 73.8 ± 7.1 0.182
Sex, woman 33 (51.6) 17 (53.1) > 0.999
Parkinson disease
HY stage 1.78 ± 0.42 3.50 ± 0.67 < 0.001
Disease duration, year 4 [2–7] 6 [4–9] 0.007
LEDD, mg 387 ± 190 642 ± 296 < 0.001
Use of anticholinergics 11 (17.2) 3 (9.4) 0.373
Trihexyphenidyl 5 (7.8) 1 (3.1)
Procyclidine 6 (9.4) 2 (6.3)
Pupillometry
NPi 4.31 ± 0.32 4.29 ± 0.35 0.760
Size, mm 3.84 ± 0.67 3.62 ± 0.71 0.148
Minimum diameter, mm 2.66 ± 0.41 2.59 ± 0.47 0.445
Percent change, % 30.2 ± 5.4 28.1 ± 5.4 0.079
Constriction velocity, mm/s 2.25 ± 0.64 1.89 ± 0.57 0.006
Maximum constriction velocity, mm/s 3.31 ± 0.90 2.79 ± 0.80 0.005
Latency of constriction, s 0.26 ± 0.03 0.25 ± 0.03 0.478
Dilation velocity, mm/s 0.99 ± 0.26 0.95 ± 0.25 0.453
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measured according to their disease progression from their initial diagnosis stage. Second, because this study 
was conducted in a single university hospital in Korea, the results should be generalized with caution. Third, 
the method employed to measure patients’ motor symptoms was limited to determining their HY stages. Infor-
mation on the patients’ UPDRS scores and other motor complications remains insufficient, and there was no 
distinction between patients with the tremor dominant type of PD and those with the postural instability-gait 
disturbance type. However, considering the previous finding that MDS-UPDRS increases in proportion to the 
HY stage, there seems to be no major problems in reflecting the disease severity of PD based on the HY  stage31. 
Fourth, all motor symptoms were evaluated in the ON state, and there are no evaluation results for the off state. 
Fifth, autonomic function tests other than pupillometry were not performed. Hence, based solely on the results 
of this study, it may be a quick conclusion to evaluate the changes in the autonomic nervous system accord-
ing to the progression of disease in PD patients. However, previous studies have reported that the PLR may be 
associated with autonomic nervous system function in PD patients. Parkinsonian motor deficits are known to 
be different among patients with similar striatal dopamine  levels32; therefore, it is thought that a parallel study 
analyzing dopamine transporter imaging is necessary to determine the extent which pupillometry results are 
related to dopaminergic deficits.
Nevertheless, this study has several strengths. The PLR was measured with a constant light stimulus using 
automated pupillometry, and the test location was constant, and the iris colors were similar due to the patients’ 
ethnicities being similar, thus minimizing the external effects of the test. Considering the results of previous 
studies showing that the PLR changes with aging, it is thought that the age-matched study design would have 
helped to improve the accuracy of this study. In addition, it is believed that using large sample size of patients 
with various stages of PD contributed to improving the accuracy of the study.
In conclusion, the parameters measured by pupillometry changed according to the motor progression of PD. 
In particular, constriction velocity and maximum constriction velocity decreased significantly, suggesting that 
pupillary parasympathetic dysfunction progresses with the progression of PD. In contrast, the factors related 
to sympathetic dysfunction did not change much, implying that pupillary sympathetic dysfunction advances 
relatively slowly even PD advanced. This study shows the possibility of observing the disease progression of PD 
by measuring the constriction velocity of the pupil using a pupilometer.
Data availability
Anonymized data and documentation from this study can be available to qualified investigators on reasonable 
request.
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